Thymalin
Immune / Anti-AgingAlso known as: Thymus Extract, Thymic Factor
Mechanism
A purified extract from the thymus gland (the immune system's training center). It boosts T-cell development and function, which declines significantly with age as the thymus shrinks. Used in Russia for decades to support immunity in elderly patients and has been studied in longevity research alongside Epithalon.
Technical detail
Polypeptide complex extracted from calf thymus containing thymic hormones including thymulin, thymopoietin, and thymosin fractions. Restores T-lymphocyte differentiation and maturation, increases CD4+/CD8+ T-cell ratio, and enhances NK cell activity. In Khavinson's longevity studies, Thymalin + Epithalon administered to elderly patients over 6 years reduced mortality by 4.1x vs controls (Khavinson, 2010). Mechanisms: restores thymic output (measured by TREC levels), normalizes cortisol/DHEA ratio, enhances antioxidant capacity.
Effects
**Immune System (Tier 2 — Russian Clinical Studies):** Thymalin is a polypeptide complex extracted from calf thymus glands, developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Contains a mixture of thymic peptides that collectively support T-cell maturation, differentiation, and function. Promotes CD4+ T helper cell differentiation, enhances CD8+ cytotoxic T cell activity, and normalizes the CD4/CD8 ratio. Restores thymic function in aging individuals where thymic involution has reduced naive T cell output. **Aging/Longevity (Tier 2 — Khavinson Bioregulator Research):** In the landmark 15-year Khavinson-Morozov clinical study (published 2003), elderly patients receiving thymalin + epithalon showed 28% reduction in mortality over 12 years compared to controls. Thymalin specifically restored immune function markers that decline with aging: thymulin activity, T-cell proliferative response, NK cell cytotoxicity. When combined with epithalon (pineal bioregulator), showed synergistic effects on mortality reduction. **Endocrine/Neuroendocrine (Tier 3):** Thymalin administration in elderly subjects restored melatonin secretion patterns and cortisol circadian rhythm. May act as a bidirectional immune-neuroendocrine regulator. Evidence of thymus-pineal axis interaction (thymalin + epithalon combination). **Hematological (Tier 2):** Stimulates bone marrow stem cell differentiation toward lymphoid lineage. Can normalize white blood cell counts in immunocompromised patients (post-chemotherapy, post-radiation, chronic infections).
Practitioner Guide
**Standard Bioregulator Protocol:** - Dose: 5-10mg IM or SC daily for 5-10 consecutive days - Cycle: repeat every 3-6 months (quarterly is most common) - Often paired with epithalon (pineal bioregulator): thymalin 10mg IM daily x 10 days + epithalon 10mg IM daily x 10 days, given concurrently - Best administered in the morning (aligns with natural cortisol/immune rhythms) **Functional Medicine Use:** - Primary indication: age-related immune decline (immunosenescence) in patients 50+ - Post-chemotherapy immune recovery: 10mg IM daily x 10 days starting 2-4 weeks post-last chemo cycle - Chronic infection support: 10mg daily x 10 days, repeat monthly until immune markers normalize - Autoimmune modulation: some practitioners report immunomodulatory (not immunostimulatory) effects — use with caution in autoimmune conditions **Practical Notes:** - Sourced primarily from Russian pharmaceutical manufacturers (Samson-Med) - Quality varies significantly between suppliers — pharmaceutical-grade thymalin from Russia is the reference standard - Some practitioners substitute with synthetic thymic peptides (thymosin alpha-1, thymulin) for more standardized dosing - Monitor CBC with differential, CD4/CD8 ratio, NK cell count before and after treatment course
Dosing Protocols
- Dose
- 5000mcg
- Frequency
- Once daily for 5-10 consecutive days; repeat 2-4x per year
- Timing
- Morning on an empty stomach
- Route
- intramuscular
- Cycle
- 1-2 weeks
Standard Russian clinical protocol: 5-10mg IM daily for 3-10 days. Thymalin is a polypeptide complex extracted from calf thymus containing thymulin, thymopoietin, and thymosin fractions. Restores T-cell differentiation, increases CD4+/CD8+ ratio, and enhances NK cell activity. Used in Russia for decades in elderly patients. Often combined with Epithalon — Khavinson's 6-year study showed Thymalin + Epithalon reduced mortality 4.1x vs controls in elderly patients.
- Dose
- 10000mcg
- Frequency
- Once daily for 10 consecutive days; repeat 1-4x per year
- Timing
- Morning on an empty stomach
- Route
- intramuscular
- Cycle
- 1-2 weeks
Higher dose protocol for significant immune compromise or as part of anti-aging combination with Epithalon. 10mg IM daily for 10 days is the upper end of the standard Khavinson protocol. In elderly patients (60-80 years), this protocol normalized thymic output (measured by TREC levels), restored cortisol/DHEA ratio, and enhanced antioxidant capacity. Repeat courses 1-4x per year based on immune status. IM injection preferred over SC for this peptide complex.
Contraindications & Cautions
- hard stop — Organ transplant / immunosuppressive therapyThymalin stimulates thymic function, T-cell maturation, and immune activation. In organ transplant recipients or patients on immunosuppressive therapy, immune stimulation may trigger acute or chronic graft rejection and directly oppose the therapeutic goal of immunosuppression.Action: Absolutely contraindicated in organ transplant recipients and patients on immunosuppressive therapy.
- hard stop — PregnancyNo adequate safety data during pregnancy. Immune-modulating peptide could affect maternal-fetal immune tolerance.Action: Do not use during pregnancy.
- hard stop — BreastfeedingNo data on excretion in breast milk. Immune-modulating effects on nursing infant unknown.Action: Do not use while breastfeeding.
- hard stop — Under 18 years of ageImmune-modulating peptide. Not for unsupervised pediatric use.Action: Do not provide to individuals under 18.
- requires physician — Autoimmune diseaseThymalin enhances T-cell function and immune surveillance. In patients with autoimmune conditions, this immune stimulation may exacerbate the autoimmune response and trigger disease flares.Action: Requires specialist evaluation by immunologist or rheumatologist. Monitor autoimmune markers closely.
Evidence
- emerging
Effect of thymalin and epithalon on immune function and lifespan in aged
Khavinson V, Morozov VG (2003) — Bulletin of Experimental Biology and Medicine
Thymalin (thymic peptide extract) administration in elderly patients over 6-8 years was associated with reduced mortality (1.6-fold) compared to untreated controls. Improvements in immune markers including T-cell counts, thymulin activity, and normalization of cytokine profiles were observed. Limited by observational design and single research group.
Stacks featuring this peptide
Based on Khavinson's landmark longevity studies where Epithalon + Thymalin reduced mortality by 4.1x in elderly patients over 6 years. Epithalon (AEDG tetrapeptide) activates telomerase, extending cellular replicative capacity and restoring pineal melatonin production. Thymalin restores thymic immune function — immune decline (immunosenescence) is a primary driver of age-related disease and infection mortality. SS-31 (Elamipretide) targets mitochondrial dysfunction, the third hallmark — it localizes to the inner mitochondrial membrane, stabilizing cardiolipin and restoring electron transport chain efficiency. NAD+ replenishes the cellular energy currency that declines ~50% from age 40-60, required by sirtuins, PARPs, and CD38 for DNA repair and epigenetic maintenance. Four hallmarks of aging addressed: telomere shortening, immunosenescence, mitochondrial dysfunction, and NAD+ depletion.
Epithalon (telomerase activation) + GHK-Cu (gene expression reset to youthful patterns) + Humanin (mitochondrial protection) + Thymalin (immune rejuvenation) + NAD+ (cellular energy restoration). Each targets a different hallmark of aging: telomere shortening, altered gene expression, mitochondrial dysfunction, immune decline, and NAD+ depletion.
Thymosin Alpha-1 (T-cell maturation, NK cell activation, approved in 35+ countries) + LL-37 (broad-spectrum antimicrobial, anti-biofilm, innate immunity) + Thymalin (thymic restoration, comprehensive immune rebalancing). Triple approach: innate defense (LL-37), adaptive immunity (TA1), and thymic rejuvenation (Thymalin).
A comprehensive thymic reconstitution and innate immune restoration protocol. Thymosin Alpha-1 (approved in 35+ countries) drives T-cell maturation and NK cell activation — the adaptive immune system's primary effectors. Thymalin (thymus extract) provides the full spectrum of thymic hormones to restore age-related thymic involution. Thymulin (FTS-Zn, requires zinc cofactor) specifically promotes T-cell differentiation marker expression (CD2, CD3, CD4). LL-37 (human cathelicidin) activates the innate immune system — direct antimicrobial activity, biofilm disruption, and chemotaxis of immune cells. Together: rebuild the thymus (Thymalin), mature new T-cells (Tα1 + Thymulin), and arm the front-line defense (LL-37). Designed for post-infection immune rebuilding, age-related immune decline, or recurrent infection patterns.
Research Summary
**Tier 1 — Established Pharmaceutical (Russia):** - Registered pharmaceutical product in Russia since 1982 (one of the first bioregulator drugs approved) - Extensive Russian clinical data: thousands of patients treated across multiple indications (immune deficiency, post-surgical, oncology adjuvant) **Tier 2 — Published Clinical Studies:** - Khavinson & Morozov (2003): 15-year prospective study in 266 elderly patients. Thymalin + epithalon group showed 28% reduction in cardiovascular mortality vs. control (published in Bulletin of Experimental Biology and Medicine) - Multiple Russian clinical studies showing restoration of T-cell subpopulations after thymalin administration in immunocompromised elderly - Thymalin + epithalon combination: 6-year study showing normalization of immune markers and melatonin secretion in elderly patients **Tier 3 — Emerging/Experimental:** - Western medical literature has limited primary research on thymalin (most data is from Russian/Soviet-era publications) - Mechanism of action at molecular level remains incompletely characterized (it is a peptide mixture, not a single defined molecule) - Ongoing interest in thymalin as a model for multi-peptide bioregulation vs. single-molecule pharmacology - Some researchers attempting to identify the specific active peptide sequences within the thymalin extract